Frontline Sunitinib Compared to Everolimus in mRCC OncLive ... favorable or intermediate prognoses. Overall, the trial did not demonstrate that first-line everolimus was noninferior to first-line sunitinib, further solidifying sunitinib as the preferred choice for patients with a favorable to intermediate ... |
